Nuvo Pharmaceuticals (NRIFF) Stock Price, News & Analysis

Company Overview

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3,000 shs
• Average Volume: 7,337 shs
• Market Capitalization: $8.52 million
• P/E Ratio: 18.69
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:NRIFF
• CIK: N/A
• Web: www.nuvopharmaceuticals.com
• Phone: (905) 673-6980
• Fax: N/A
• Employees: 99
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 18.69
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.53 million
• Net Margins: -2.81%
• Pretax Margin: N/A
• Return on Equity: 8.02%
• Return on Assets: 1.11%

Debt

• Debt-to-Equity Ratio: 5.27
• Current Ratio: 2.67
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $52.41 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.82
• Book Value: $1.59 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,400,000
• Free Float: N/A
• Market Cap: $8.52 million
• Optionable: Not Optionable
• Beta: 1.57